NASDAQ | TSX: ACB
The collaboration aims to broaden access of
premium medical cannabis products to Australian patients
EDMONTON, AB, Dec. 17,
2024 /PRNewswire/ - Aurora Cannabis Inc.
(NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical
cannabis company, is pleased to announce a distribution partnership
between The Entourage Effect and MedReleaf Australia. The Entourage
Effect provides comprehensive distribution and support services to
pharmacies in Australia and will
serve as a wholesaler for MedReleaf Australia's leading portfolio
of products under the CraftPlant, Aurora, and IndiMed brands,
furthering the mission to expand access for Australian
patients.
"We are deeply committed to broadening access to premium medical
cannabis for the expanding community of patients who rely on
Aurora, and we seek the right partners in the markets in which we
operate to make this happen," said Andre
Jerome, Executive Vice President, Global Business
Development at Aurora. "Our new partnership with The Entourage
Effect broadens our already robust distribution in Australia, ensuring even greater access to our
high-quality medical cannabis portfolio, reinforcing our commitment
to patient care."
"We are thrilled to be partnering with MedReleaf Australia to
facilitate the distribution and wholesaling of their products,"
said Lisa Varley, CEO of The
Entourage Effect. "This collaboration marks a significant milestone
for both companies, underscoring our shared commitment to improving
patient access and advancing the Australian medicinal cannabis
market. Together, we are well-positioned to better serve the needs
of patients across the nation."
Aurora remains at the forefront of the global medical cannabis
industry and is steadfast in supporting the continued growth and
development of the rapidly expanding Australian medical cannabis
market. MedReleaf Australia, a wholly owned subsidiary of Aurora,
is committed to quality, consistency and proudly meets all TGA-GMP
standards.
For further information about medical cannabis products, doctors
and health care professionals can contact MedReleaf Australia's
clinical support team or visit their website:
www.medreleafaustralia.com.au.
About Aurora Cannabis Inc.
Aurora is opening the world to cannabis, serving both the
medical and consumer markets across Canada, Europe, Australia and South
America. Headquartered in Edmonton, Alberta, Aurora is a pioneer in
global cannabis, dedicated to helping people improve their lives.
The Company's adult-use brand portfolio includes Drift, San Rafael
'71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis
brands include MedReleaf, CanniMed, Aurora and Whistler Medical
Marijuana Co., as well as international brands, Pedanios, Bidiol,
IndiMed and CraftPlant. Aurora also has a controlling interest in
Bevo Farms Ltd., North America's
leading supplier of propagated agricultural plants. Driven by
science and innovation, and with a focus on high-quality cannabis
products, Aurora's brands continue to break through as industry
leaders in the medical, wellness and adult recreational markets
wherever they are launched. Learn more at
www.auroramj.com and follow us
on X and LinkedIn.
Aurora's common shares trade on the NASDAQ and TSX under the
symbol "ACB".
Forward Looking Information:
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements").
Forward-looking statements are frequently characterized by words
such as "plan", "continue", "expect", "project", "intend",
"believe", "anticipate", "estimate", "may", "will", "potential",
"proposed" and other similar words, or statements that certain
events or conditions "may" or "will" occur. Forward-looking
statements made in this news release include, but are not limited
to, statements regarding the distribution partnership between
MedReleaf Australia and The Entourage Effect, expectations for the
partnership to broaden access of premium medical cannabis products
to Australian patients, and the Company's ongoing commitment to
patient care and access and advancing the Australian medical
cannabis market.
These forward-looking statements are only predictions. Forward
looking information or statements contained in this news release
have been developed based on assumptions management considers to be
reasonable. Material factors or assumptions involved in developing
forward-looking statements include, without limitation, publicly
available information from governmental sources as well as from
market research and industry analysis and on assumptions based on
data and knowledge of this industry which the Company believes to
be reasonable. Forward-looking statements are subject to a variety
of risks, uncertainties and other factors that management believes
to be relevant and reasonable in the circumstances could cause
actual events, results, level of activity, performance, prospects,
opportunities or achievements to differ materially from those
projected in the forward-looking statements. These risks include,
but are not limited to, the ability to retain key personnel, the
ability to continue investing in infrastructure to support growth,
the ability to obtain financing on acceptable terms, the continued
quality of our products, customer experience and retention, the
development of third party government and non-government consumer
sales channels, management's estimates of consumer demand in
Canada and in jurisdictions where
the Company exports, expectations of future results and expenses,
the risk of successful integration of acquired business and
operations (with respect to the Transaction and more generally with
respect to future acquisitions), management's estimation that
SG&A will grow only in proportion of revenue growth, the
ability to expand and maintain distribution capabilities, the
impact of competition, the general impact of financial market
conditions, the yield from cannabis growing operations, product
demand, changes in prices of required commodities, competition, and
the possibility for changes in laws, rules, and regulations in the
industry, epidemics, pandemics or other public health crises and
other risks, uncertainties and factors set out under the heading
"Risk Factors" in the Company's annual information from dated
June 20, 2024 (the "AIF") and filed
with Canadian securities regulators available on the Company's
issuer profile on SEDAR+ at www.sedarplus.com and filed with
and available on the SEC's website at www.sec.gov. The Company
cautions that the list of risks, uncertainties and other factors
described in the AIF is not exhaustive and other factors could also
adversely affect its results. Readers are urged to consider the
risks, uncertainties and assumptions carefully in evaluating the
forward-looking statements and are cautioned not to place undue
reliance on such information. The Company is under no obligation,
and expressly disclaims any intention or obligation, to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as expressly
required by applicable securities law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aurora-announces-distribution-partnership-between-medreleaf-australia-and-the-entourage-effect-302333188.html
SOURCE Aurora Cannabis Inc.